{"id":"W4293083608","doi":"10.1200/jco.2022.40.17_suppl.lba2002","title":"Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600–mutant pediatric low-grade glioma (pLGG).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Trametinib; Internal medicine; Clinical endpoint; Dabrafenib; Phases of clinical research; Oncology; Randomized controlled trial; Progression-free survival; Carboplatin; Cancer; Surgery; Clinical trial; Chemotherapy; Metastatic melanoma; Vemurafenib; Cisplatin; Kinase; MAPK/ERK pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001785125,0.00168489,0.002178631,0.0003248171,0.0003956936,0.001128277,0.001069317,0.001303712,0.007518975],"category_scores_gemma":[0.001356081,0.0007678944,0.001874454,0.0003624392,0.0007479481,0.0008093058,0.0003719128,0.003230953,0.001576824],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001380416,"about_ca_system_score_gemma":0.001822559,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001506631,"about_ca_topic_score_gemma":0.004999713,"domain_scores_codex":[0.9994899,0.000262074,0.00002315517,0.00009175349,0.00003336498,0.00009971276],"domain_scores_gemma":[0.9990445,0.0001345751,0.0002013035,0.00006609668,0.00006597085,0.0004876283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9519356,0.01182435,0.00191291,0.0007246769,0.001401187,0.0001152088,0.00007917671,0.0008385916,0.007684154,0.0001191615,0.004265963,0.01909904],"study_design_scores_gemma":[0.8708383,0.1200989,0.004611629,0.00004042947,0.0008647864,0.0001380763,0.00003292983,0.0005842022,0.0008315431,0.0001839964,0.001757212,0.00001806256],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716798,0.00472569,0.001050282,0.001694936,0.0006490804,0.00932382,0.00551697,0.0002910651,0.005068282],"genre_scores_gemma":[0.9797431,0.002120221,0.001626241,0.001698297,0.0002850544,0.006487419,0.004115634,0.00005589854,0.003868074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007518975,"threshold_uncertainty_score":0.02515346,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08595484011169645,"score_gpt":0.4438902196553616,"score_spread":0.3579353795436652,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}